



Correction

Correction: Yan, L., et al. Combined Taurine, Epigallocatechin Gallate and Genistein Therapy Reduces HSC-T6 Cell Proliferation and Modulates the Expression of Fibrogenic Factors. *Int. J. Mol. Sci.* 2013, 14, 20543–20554

Yan Li ¹, Ying Luo ², Xuerong Zhang ², Xing Lin ², Min He ² and Ming Liao ^{2,*}

¹ College of Animal Science and Technology, Guangxi University, Nanning 530004, China; liyan01091@163.com

² Medical Scientific Research Center, Guangxi Medical University, Nanning 530021, China;

luoyingyiy@163.com (Y.L.); xuerongzhang86@126.com (X.Z.); linxingyk@163.com (X.L.);

heminmin163@163.com (M.H.)

* Correspondence: lminggx@163.com; Tel.: +86-0771-5353495

The authors regret that, during the preparation of our published manuscript “Combined taurine, epigallocatechin gallate and genistein therapy reduces HSC-T6 cell proliferation and modulates the expression of fibrogenic factors” [1], we submitted an incorrect version of Figure 2. Thus, Figure 2 should be replaced with the following figure (Figure 1).

The correction does not change the scientific conclusions of the article in any way. The authors apologize for any confusion this error may have caused to the readers.



Citation: Li, Y.; Luo, Y.; Zhang, X.; Lin, X.; He, M.; Liao, M. Correction: Yan, L., et al. Combined Taurine, Epigallocatechin Gallate and Genistein Therapy Reduces HSC-T6 Cell Proliferation and Modulates the Expression of Fibrogenic Factors. *Int. J. Mol. Sci.* 2013, 14, 20543–20554. *Int. J. Mol. Sci.* 2021, 22, 2343. <https://doi.org/10.3390/ijms22052343>

Received: 12 January 2021

Accepted: 14 January 2021

Published: 26 February 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.




Figure 1. Cont.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).




Figure 1. The mRNA expression levels of genes associated with hepatic fibrogenesis in HSC-T6 cells treated with a combination of taurine, EGCG and genistein. Semi-quantitative PCR data are shown for cells treated with a combination of taurine, EGCG and genistein in varying doses. The relative mRNA expression levels of *TGF-β1* (A), *Col-1* (B), *TIMP-1* (C), *TIMP-2* (D), and *MMP-2* (E) are presented; the upper panels show representative pictures of agarose gels and the lower panels show relative quantification of mRNA expression levels in (I) untreated control cells, or cells treated with (II) 0.015 mg/mL taurine, 0.0175 mg/mL EGCG and 0.0035 mg/mL genistein, (III) 0.03 mg/mL taurine, 0.035 mg/mL EGCG and 0.007 mg/mL genistein, or (IV) 0.06 mg/mL taurine, 0.07 mg/mL EGCG and 0.014 mg/mL genistein. (M) Marker. Data are presented as the mean ± S.E.; * $p < 0.05$ vs. group I (untreated control).

Conflicts of Interest: The authors declare no conflict of interest.

Reference

- Li, Y.; Luo, Y.; Zhang, X.; Lin, X.; He, M.; Liao, M. Combined Taurine, Epigallocatechin Gallate and Genistein Therapy Reduces HSC-T6 Cell Proliferation and Modulates the Expression of Fibrogenic Factors. *Int. J. Mol. Sci.* **2013**, *14*, 20543–20554. [[CrossRef](#)] [[PubMed](#)]